论文部分内容阅读
目的观察静脉补铁与口服补铁治疗维持性血液透析患者肾性贫血的疗效。方法选择MHD患者36例,随机分为A组(促红细胞生成素+静脉补铁+口服维生素E)和B组(促红细胞生成素+口服补铁)。结果两组患者治疗后血红蛋白均明显升高,但两组网织红细胞变化相对治疗前无明显差异。结论对于不能耐受口服铁剂或其疗效欠佳的MHD患者,静脉应用蔗糖铁是一个安全有效的选择。
Objective To observe the curative effect of intravenous iron supplementation and oral iron supplementation on renal anemia in maintenance hemodialysis patients. Methods Thirty-six patients with MHD were selected and randomly divided into group A (erythropoietin + intravenous iron + oral vitamin E) and group B (erythropoietin + oral iron). Results After treatment, hemoglobin in both groups were significantly increased, but there was no significant difference in reticulocyte changes between the two groups before treatment. Conclusion Intravenous application of sucrose iron is a safe and effective option for MHD patients who can not tolerate oral iron or whose efficacy is poor.